Fate Therapeutics
FATE
227 hedge funds and large institutions have $1.06B invested in Fate Therapeutics in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 97 increasing their positions, 59 reducing their positions, and 43 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 59
9% more call options, than puts
Call options by funds: $998K | Put options by funds: $916K
2.98% less ownership
Funds ownership: 111.16% → 108.18% (-3%)
5% less funds holding
Funds holding: 239 → 227 (-12)
19% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 43
56% less capital invested
Capital invested by funds: $2.41B → $1.06B (-$1.35B)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$41.8M |
| 2 |
BlackRock
New York
|
+$34M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.2M |
| 4 |
Two Sigma Investments
New York
|
+$24.7M |
| 5 |
Renaissance Technologies
New York
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$140M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$49.6M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$29.4M |
| 4 |
Janus Henderson Group
London,
|
-$26.5M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$17.8M |
FATE Hedge Fund Activity: Q4 2022 in Review
227 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2022, worth a combined $1.06B — down 56% from $2.41B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of FATE and 35 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 97 added.
The largest buyer was Millennium Management, adding an estimated $41.8M. The largest seller was ARK Investment Management, cutting an estimated $140M.
- 227 institutional investors held Fate Therapeutics (FATE) as of Q4 2022, down from 239 in Q3 2022.
- Funds reported $1.06B of Fate Therapeutics stock for Q4 2022, down 56% quarter-over-quarter.
- 35 funds opened new Fate Therapeutics positions in Q4 2022 and 43 closed out, a net change of -8 holders.
- The largest Fate Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $41.8M added.
- The largest Fate Therapeutics seller in Q4 2022 was ARK Investment Management, an estimated $140M sold.
Based on aggregated 13F filings for Q4 2022.